Deuruxolitinib Phosphate + Deuruxolitinib Interaction
Moderateinteraction on record
Description
Deuruxolitinib is a CYP2C9 and CYP3A substrate. Concomitant use with a strong CYP3A and moderate or strong CYP2C9 inducer decreases deuruxolitinib exposure (C max and AUC), which may reduce LEQSELVI efficacy [see Clinical Pharmacology ( 12.3 )] . Deuruxolitinib is a CYP2C9 substrate.
Source: FDA drug label - deuruxolitinib phosphate